Immunic Reports Q3 2026 Results; Cash of $132 Million

Immunic reported a third-quarter 2026 net loss of $42.3 million, or $0.99 per share, compared with a $25.6 million loss a year earlier. Operating expenses were $43.4 million, and cash and cash equivalents totaled $132.0 million at quarter-end. The company said its Phase 3 ENSURE trials remain on tr…